Know what's inside.

Your Challenges Require Smart Solutions

At GBA Pharma, we have broad experience in handling small molecules as well as larger molecules, biologics and cell based therapies.

We can support your projects from early lead optimization and early preclinical stage to clinical studies with our GMP Depots, EU GMP manu­facturing site for labelling and packaging and QP services, as well as late drug development and analytical services including import testing and QP batch release.

Preclinical Services

For nearly 20 years the GBA site at Saarbrücken leverages the expertise of our highly qualified team to provide tailor-made drug discovery & develop­ment solutions. We offer GLP and non-GLP studies for exploratory or regulatory demands. Our portfolio covers in vitro, in vivo, ex vivo and bioanalytical services. › more

Analytical Services

Our locations for analytical services support you in the development, approval process, and quality control of your products with an extensive range of services › more

Clinical Trial Supply Management

We focus on complex clinical trial designs and offer a unique combination of logistic services through our global network. It is precisely this flexibility and personal approach that differentiates us from our competitors. › more

Central Laboratory Services

LKF - Laboratorium für Klinische Forschung GmbH – was established in 1991. The founder, Prof. Dr. W. Junge, M.D., after experience of clinical trials in his medical routine laboratory, recog­nized the necessity and advantage of for­ming a separate and specialized medical laboratory unit dedicated exclusively to supporting clinical trials of phases I – IV. › more

GBA Pharma was formed by mergers of five formerly independent companies located in Germany and Austria: Pharmacelsus GmbH (Saarbrücken), Phytos Labor für Analytik von Arzneimitteln GmbH & Co. KG (Neu-Ulm), LPU Labor für Pharma- und Umweltanalytik GmbH (Martinsried, Gräfelfing), and ABF Pharmaceutical Services GmbH (Vienna). Our clients range from pharmaceutical and biotechnology companies to service providers; contract research and contract manufacturing organizations and academic institutions. The Headquarter of GBA Pharma division is located in Martinsried (Munich area); one of the hot spots of pharmaceutical and biotechnology in Europe. All German sites are operating as branches of GBA Pharma GmbH and our Austrian site is a hundred percent subsidiary called GBA Pharma Austria GmbH.

All merged companies have one key characteristic in common: stable and trusting long-standing relationships with our clients.  This is result of the high quality of services, reliable timelines, state of the art portfolio of methods and equipment combined with academic resilience to solve problems.

We have extensive experience in the pharmaceutical industry. Each of our subsidiaries have an operational experience of 12 to 38 years. Majority of our staff are academically educated to post-graduate level. 90% annual repeat business is a testimony of our emphasis on becoming a trusted extension of your team and facilitation your success by delivering high quality services combined with an outstanding scientific expertise.

GBA Pharma Provides Solutions

Our services are divided into four categories:

  • Preclinical in vivo & in vitro studies & bioanalysis 
  • Pharmaceutical testing
  • Clinical trial supply management
  • Regulatory guidance in the above mentioned fields

In the mentioned fields we are working in strict compliance with the regulatory requirements, such as but not limited to:

  • GLP and GCLP in Saarbrücken
  • GMP in Neu-Ulm, Martinsried, Gräfelfing & Vienna
  • GMP FDA inspected in Neu-Ulm & Martinsried

Brands of

Exhibition Dates

14th - 15th May 2019
Outsourcing in Clinical Trials Europe 2019
Milan, Italy

14th - 15th May 2019
Clinical Trial Supply West Coast
Burlingame (SFC), USA

03rd - 06th June 2019
Bio International
Philadelphia, USA

11th - 12th June 2019
London, UK

25th - 28th July 2019
Bio Taiwan
Taipei, Taiwan


Dr. Xaver Schratt from GBA Pharma Labs speaking at Impurities Forum 2019.

On June 26th and 27th the Impurities Forum will take place in Prague. The focus is on ‘General Strategies for Investigation and Control’ as well as ‘Elemental Impurities and Genotoxic Impurities’.Part I of the event is designed to provide a comprehensive review of impurities analysis and characterisation in drug substances and drug products and their recording and reporting. In Part II of the Impurities Forum the key principles of the ICH Q3D Guideline will be highlighted. You will get to know the essential aspects and approaches of determining and controlling elemental impurities in drug prod more

Pharmaceutical Industry Brexit Update: Extension of the period under ‘Article 50’

The European Council agreed to a further extension of the date for the UK’s withdrawal from the EU at its meeting on 10-11 April. The extension will last as long as necessary and, in any event, no longer than 31 October 2019. EMA calls on all pharmaceutical companies to continue their preparedness for the UK’s withdrawal. more